US 12,390,505 B2
Composition for preventing or treating obesity or diabetes, comprising acanthopanax senticosus extract and garcinia cambogia extract or compound isolated therefrom
Su Ui Lee, Daejeon (KR); Hyung Won Ryu, Daejeon (KR); Mun Ock Kim, Daejeon (KR); Sei Ryang Oh, Daejeon (KR); Doo Young Kim, Daejeon (KR); and Hyun Jae Jang, Daejeon (KR)
Assigned to KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, Daejeon (KR)
Appl. No. 18/024,604
Filed by KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, Daejeon (KR)
PCT Filed Aug. 18, 2021, PCT No. PCT/KR2021/010925
§ 371(c)(1), (2) Date Mar. 3, 2023,
PCT Pub. No. WO2022/050601, PCT Pub. Date Mar. 10, 2022.
Claims priority of application No. 10-2020-0112341 (KR), filed on Sep. 3, 2020; and application No. 10-2021-0075749 (KR), filed on Jun. 10, 2021.
Prior Publication US 2023/0364170 A1, Nov. 16, 2023
Int. Cl. A61K 36/258 (2006.01); A61K 31/194 (2006.01); A61K 31/585 (2006.01); A61K 36/38 (2006.01); A61P 3/04 (2006.01); A61P 3/08 (2006.01)
CPC A61K 36/258 (2013.01) [A61K 31/194 (2013.01); A61K 31/585 (2013.01); A61K 36/38 (2013.01); A61P 3/04 (2018.01); A61P 3/08 (2018.01)] 10 Claims
OG exemplary drawing
 
1. A pharmaceutical composition for treating diabetes or obesity, comprising a first component of Acanthopanax extract, chiisanogenin, or chiisanogenin derivative, and a second component of Garcinia cambogia extract or hydroxy citric acid (HCA).